Leukemia Clinical Trials in Chicago

Showing 541-560 of 821 trials

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

NCT02109653

This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.

Non-Small Cell Lung Cancer

Array Biopharma, now a wholly owned subsidiary of PfizerStarted Jun 2015

Chicago, Illinois, United States

TERMINATEDPHASE1/PHASE22.2 miles

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

NCT03026166

The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).

Small Cell Lung Cancer

AbbVie42 participantsStarted Mar 2017

La Jolla, California, United States • Orlando, Florida, United States • Athens, Georgia, United States +32 more locations

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Leukemia Trials in Other Cities

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Analyses of Human Samples Collected in Clinical Trials

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Study Comparing OsseoSpeed™ Implants of Two Different Lengths in the Upper and Lower Posterior Jaw

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Clinical Trial Evaluating Acutrak Headless Compression Screw Fixation of Medial Malleolus Fractures

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Prospective Multicenter Trial to Compare Preformed vs Non Preformed Orbital Implants

Other Conditions in Chicago